In vitro steroid resistance correlates with outcome in severe alcoholic hepatitis

Hepatology

Volumn 53, Issue 4, 2011, Pages 1316-1322

  di Mambro, A J ^a,b   Parker, R ^b   Mccune, A ^b   Gordon, F ^b   Dayan, C M ^a,b   Collins, P ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; BILIRUBIN; CORTICOSTEROID; DEXAMETHASONE; INTERLEUKIN 2 RECEPTOR; PREDNISOLONE;

ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; BILIRUBIN BLOOD LEVEL; CELL ISOLATION; CORTICOSTEROID THERAPY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; BILIRUBIN; DRUG RESISTANCE; HEPATITIS, ALCOHOLIC; HUMANS; INTERLEUKIN-2; PREDNISOLONE; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 79953747553     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24159     Document Type: Article

References (46)

1. Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75: 193-199.
2. Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. HEPATOLOGY 2005; 41: 353-358.
3. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). HEPATOLOGY 2007; 45: 797-805.
4. Forrest EH, Fisher NC, Singhal S, Brind A, Haydon G, O'Grady J, et al. Comparison of the Glasgow Alcoholic Hepatitis Score and the ABIC Score for the assessment of alcoholic hepatitis. Am J Gastroenterol; 105: 701-702.
5. Louvet A, Wartel F, Castel H, Dharancy S, Hollebecque A, Canva-Delcambre V, et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009; 137: 541-548.
6. Menon KV, Gores GJ, Shah VH. Pathogenesis, diagnosis, and treatment of alcoholic liver disease. Mayo Clin Proc 2001; 76: 1021-1029.
7. Laso FJ, Iglesias-Osma C, Ciudad J, Lopez A, Pastor I, Torres E, et al. Alcoholic liver cirrhosis is associated with a decreased expression of the CD28 costimulatory molecule, a lower ability of T cells to bind exogenous IL-2, and increased soluble CD8 levels. Cytometry 2000; 42: 290-295.
8. Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis-a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008; 27: 1167-1178.
9. Mathurin P, Abdelnour M, Ramond MJ, Carbonell N, Fartoux L, Serfaty L, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. HEPATOLOGY 2003; 38: 1363-1369.
10. Louvet A, Diaz E, Dharancy S, Coevoet H, Texier F, Thevenot T, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008; 48: 465-470.
11. Kendrick SF, Henderson E, Palmer J, Jones DE, Day CP. Theophylline improves steroid sensitivity in acute alcoholic hepatitis. HEPATOLOGY 2010; 52: 126-131.
12. Corrigan CJ. Glucocorticoid-resistant asthma. T-lymphocyte defects. Am J Respir Crit Care Med 1996; 154: S53-55; discussion S55-57.
13. Hearing SD, Norman M, Probert CS, Haslam N, Dayan CM. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 1999; 45: 382-388.
14. Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 2003; 178: 339-346.
15. Kirkham BW, Corkill MM, Davison SC, Panayi GS. Response to glucocorticoid treatment in rheumatoid arthritis: in vitro cell mediated immune assay predicts in vivo responses. J Rheumatol 1991; 18: 821-825.
16. Creed TJ, Norman MR, Probert CS, Harvey RF, Shaw IS, Smithson J, et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003; 18: 65-75.
17. Hearing SD, Norman M, Dayan CM. In vitro measurement of lymphocyte steroid sensitivity: lack of agreement between whole blood culture and separated lymphocyte culture. Immunopharmacol Immunotoxicol 1999; 21: 41-53.
18. Goleva E, Li LB, Leung DY. IFN-gamma reverses IL-2- and IL-4-mediated T-cell steroid resistance. Am J Respir Cell Mol Biol 2009; 40: 223-230.
19. Leung DY, Spahn JD, Szefler SJ. Steroid-unresponsive asthma. Semin Respir Crit Care Med 2002; 23: 387-398.
20. Leung DY, Bloom JW. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2003; 111: 3-22.
21. Creed TJ, Lee RW, Newcomb PV, di Mambro AJ, Raju M, Dayan CM. The effects of cytokines on suppression of lymphocyte proliferation by dexamethasone. J Immunol 2009; 183: 164-171.
22. Lee RW, Creed TJ, Schewitz LP, Newcomb PV, Nicholson LB, Dick AD, et al. CD4+CD25(int) T cells in inflammatory diseases refractory to treatment with glucocorticoids. J Immunol 2007; 179: 7941-7948.
23. Forrest EH, Evans CD, Stewart S, Phillips M, Oo YH, McAvoy NC, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005; 54: 1174-1179.
24. Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. HEPATOLOGY 2007; 45: 1348-1354.
25. Morris JM, Forrest EH. Bilirubin response to corticosteroids in severe alcoholic hepatitis. Eur J Gastroenterol Hepatol 2005; 17: 759-762.
26. Seki M, Ushiyama C, Seta N, Abe K, Fukazawa T, Asakawa J, et al. Apoptosis of lymphocytes induced by glucocorticoids and relationship to therapeutic efficacy in patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41: 823-830.
27. Haczku A, Alexander A, Brown P, Assoufi B, Li B, Kay AB, et al. The effect of dexamethasone, cyclosporine, and rapamycin on T-lymphocyte proliferation in vitro: comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma. J Allergy Clin Immunol 1994; 93: 510-519.
28. Hearing SD, Norman M, Smyth C, Foy C, Dayan CM. Wide variation in lymphocyte steroid sensitivity among healthy human volunteers. J Clin Endocrinol Metab 1999; 84: 4149-4154.
29. Creed TJ, Probert CS, Norman MN, Moorghen M, Shepherd NA, Hearing SD, et al. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther 2006; 23: 1435-1442.
30. Carithers RL Jr, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989; 110: 685-690.
31. Maddrey WC. Alcoholic hepatitis: pathogenesis and approaches to treatment. Scand J Gastroenterol Suppl 1990; 175: 118-130.
32. Mathurin P, Duchatelle V, Ramond MJ, Degott C, Bedossa P, Erlinger S, et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996; 110: 1847-1853.
33. Morgan TR. Prednisolone in severe alcoholic hepatitis. N Engl J Med 1992; 327: 284-285.
34. Porter HP, Simon FR, Pope CE 2nd, Volwiler W, Fenster LF. Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial. N Engl J Med 1971; 284: 1350-1355.
35. Rambaldi A, Iaquinto G, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease: a Cochrane review. Am J Gastroenterol 2002; 97: 1674-1681.
36. Ramond MJ, Poynard T, Rueff B, Mathurin P, Theodore C, Chaput JC, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992; 326: 507-512.
37. Spahr L, Rubbia-Brandt L, Pugin J, Giostra E, Frossard JL, Borisch B, et al. Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood. J Hepatol 2001; 35: 582-589.
38. Onrust SV, Wiseman LR. Basiliximab. Drugs 1999; 57: 207-213; discussion 214.
39. Creed TJ, Probert CS. Review article: steroid resistance in inflammatory bowel disease - mechanisms and therapeutic strategies. Aliment Pharmacol Ther 2007; 25: 111-122.
40. Kam JC, Szefler SJ, Surs W, Sher ER, Leung DY. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol 1993; 151: 3460-3466.
41. Tsitoura DC, Rothman PB. Enhancement of MEK/ERK signaling promotes glucocorticoid resistance in CD4+ T cells. J Clin Invest 2004; 113: 619-627.
42. Zubiaga AM, Munoz E, Huber BT. IL-4 and IL-2 selectively rescue Th cell subsets from glucocorticoid-induced apoptosis. J Immunol 1992; 149: 107-112.
43. Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. HEPATOLOGY 2004; 39: 1390-1397.
44. Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135: 1953-1960.
45. Sharma P, Kumar A, Sharma BC, Sarin SK. Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial. J Hepatol 2009; 50: 584-591.
46. Yu CH, Xu CF, Ye H, Li L, Li YM. Early mortality of alcoholic hepatitis: a review of data from placebo-controlled clinical trials. World J Gastroenterol 2010; 16: 2435-2439.